Stock BDTX BLACK DIAMOND THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Black Diamond Therapeutics, Inc. OTC Markets

Equities

BDTX

US09203E1055

Delayed OTC Markets
Other stock markets
 		5-day change 1st Jan Change
- USD -.--% Intraday chart for Black Diamond Therapeutics, Inc. -.--% -.--%
16/05 HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating MT
09/05 Black Diamond Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating
MT
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
GL
Black Diamond: Q1 Earnings Snapshot
AQ
Black Diamond Therapeutics : Reports First Quarter 2024 Financial Results and Provides Corporate Update - Form 8-K
PU
Black Diamond Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GL
Black Diamond Therapeutics, Inc. Announces Board and Committee Changes
CI
Black Diamond Therapeutics Announces Changes to Board of Directors
GL
Wedbush Adjusts Price Target on Black Diamond Therapeutics to $16 From $10 After Market Confirmation for Drug, Maintains Outperform Rating
MT
Black Diamond Therapeutics Says BDTX-1535 Potentially Inhibits Non-Classical Mutations in Non-Small Cell Lung Cancer Patients
MT
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
GL
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
AQ
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
GL
Black Diamond: Q4 Earnings Snapshot
AQ
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
GL
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
AQ
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
GL
Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BDTX Stock
  4. BDTX Stock
  5. News Black Diamond Therapeutics, Inc.